Abbott Set to Launch First Pulsed Field Ablation Device in 2025

Abbott plans to launch its first Pulsed Field Ablation (PFA) device outside of the U.S. in 2025, with CEO Robert Ford expecting to receive the CE Mark for the device in the first half of the year and FDA approval in 2026. The Volt PFA system, which uses high-voltage electrical pulses for treating heart arrhythmias, offers a promising alternative to existing methods involving heat or cold. Abbott anticipates rapid adoption of the technology due to its speed and lower complication rates. The company faces competition from Medtronic, Boston Scientific, and Johnson & Johnson, but Abbott remains confident in its position, especially in the electrophysiology and mapping segments. In 2024, Abbott’s electrophysiology business grew by 12.3% to $2.47 billion, with strong growth expected to continue as the Volt system is introduced.

Abbott also reported growth in its diabetes care business, with sales reaching $6.81 billion in 2024, an 18.1% increase year over year, driven by the success of its continuous glucose monitors (CGMs). Ford sees significant opportunities in the international market, particularly among intensive insulin users who don’t yet use CGMs, and among individuals on basal insulin. The company is also expanding sales of its Lingo over-the-counter glucose sensors and plans to enhance connectivity with insulin pumps. Abbott’s strategic focus on structural heart and diabetes care is expected to continue driving growth in 2025.